Brief: Novonesis CFO: Slow Regulatory Approvals Are Main Obstacle To Growth

Novozymes A/S

18/06/2024 09:21

June 18 (Reuters) - NOVOZYMES A/S  NSISb.CO  CFO RAINER
LEHMANN SAY IN INTERVIEW AHEAD OF THE COMPANY'S CAPITAL MARKETS
DAY:
    * WE ARE AT AN INFLECTION POINT OF WHAT BIOSOLUTIONS CAN DO
    * THE MAIN OBSTACLE TO GROWTH OF OUR BUSINESS IS THE
REGULATORY
PART; APPROVAL OF A NEW PRODUCT IN THE EU CAN TAKE 6-8 YEARS
VERSUS 2 YEARS IN THE U.S.
    * GROWTH IN OUR BIOETHANOL BUSINESS WILL MAINLY COME FROM
INDIA
    * GROWTH OF OUR HOUSEHOLD ENZYME BUSINESS WILL MAINLY COME
FROM
EMERGING MARKETS

FURTHER COMPANY COVERAGE:  NSISb.CO 

 (Reporting by Jacob Gronholt-Pedersen)
 ((jacob.pedersen@thomsonreuters.com;))